Boston-based healthcare company PureTech Health has appointed Feng Zhang, Ph.D. to its Scientific Advisory Board (SAB), as well as Jeff Stevens, as Vice President of Growth Strategy & Operations and has expanded its team of senior advisors to include Meghan Fitzgerald, DrPH, Executive Vice President of Corporate Strategy, M&A and Health Policy at Cardinal Health; Atul Pande, M.D., Former Senior Vice President and Head of Neurosciences at GlaxoSmithKline; and Philip J. Larsen, M.D., Ph.D., Global Head of Diabetes Research & Development at Sanofi.
“We are very pleased to add these accomplished leaders to our team and advisory group of distinguished scientists and clinicians,” said Daphne Zohar, Chief Executive Officer of PureTech Health. “Insights from this group will further add to the intellectual capital resident at PureTech as we advance and enhance our pipeline.”
According to PureTech, Feng Zhang, Ph.D., will join PureTech as a member of the Company’s SAB. He is an accomplished bioengineer focused on developing tools to better understand nervous system function and disease. His lab applies these novel tools to interrogate gene function and study neuropsychiatric diseases in animal and stem cell models. Since joining MIT and the Broad Institute in January 2011, Dr. Zhang has pioneered the development of genome editing tools for use in eukaryotic cells – including human cells – from natural microbial CRISPR systems.